arXiv Preprint Archive
February 4, 2021
Erik D. Fagerholm, Robert Leech, Steven C. R. Williams et al.
The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment...
Schizophrenia Bulletin Open
2020
M. Sami, R. Mccutcheon, U. Ettinger et al.
Both chronic cannabis use and psychotic disorders are associated with abnormalities in visual attentional processing. Using functional magnetic resonance imaging (fMRI), we sought to determine whether there would be a difference in functional connectivity in patients and controls with and without a history of cannabis use in the visual and dorsal attention networks. Resting-state fMRI data were...
European Neuropsychopharmacology
July 1, 2018
Marco Colizzi, P. McGuire, Vincent Giampietro et al.
Cannabis use has been associated with psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (-)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in...
International Journal of Clinical and Experimental Hypnosis
March 24, 2012
Quinton Deeley, David A Oakley, Brian Toone et al.
149 citations
Debate regarding the neural basis of the hypnotic state continues, but a recent hypothesis suggests that it may produce alterations in the default mode network (DMN). DMN describes a network of brain regions more active during low-demand compared to high-demand task conditions and has been linked to processes such as task-independent thinking, episodic memory, semantic processing, and...